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Particle Replication in Non-Wetting Templates (PRINT) is a platform particle drug delivery technology that coopts the precision
and nanoscale spatial resolution inherently aﬀorded by lithographic techniques derived from the microelectronics industry to
produce precisely engineered particles. We describe the utility of PRINT technology as a strategy for formulation and delivery
of small molecule and biologic therapeutics, highlighting previous studies where particle size, shape, and chemistry have been
used to enhance systemic particle distribution properties. In addition, we introduce the application of PRINT technology towards
respiratorydrugdelivery,aparticularinterestduetothepharmaceuticalneedforincreasedcontroloverdrypowdercharacteristics
to improve drug delivery and therapeutic indices. To this end, we have produced dry powder particles with micro- and nanoscale
geometric features and composed of small molecule and protein therapeutics. Aerosols generated from these particles show
attractive properties for eﬃcient pulmonary delivery and diﬀerential respiratory deposition characteristics based on particle
geometry.Thisworkhighlightstheadvantagesofadoptingprovenmicrofabricationtechniquesinachievingunprecedentedcontrol
over particle geometric design for drug delivery.
1.Introduction
Particulate drug delivery systems play an important role in
the treatment of human disease. Particles such as liposomes,
protein nanoparticles, and PLGA microparticles are current-
ly used in marketed drug products using a variety of dosage
forms[1,2].Inparticular,particleaerosolinhalationtherapy
is commonplace for the treatment of respiratory disease.
Inhaled therapy using pressurized metered dose inhalers
(pMDI), dry powder inhalers (DPI), and nebulizers is an
attractive route for treatment of respiratory disease, allowing
for local delivery of high concentrations of therapeutics in
the lung and avoidance of systemic toxicities associated with
oral or injectable therapies [3–6]. Despite the prevalence of
aerosol therapy, direct drug delivery to the site of disease
remains surprisingly ineﬃcient in part due to the lack of
control of particle properties, including particle size, in the
drug formulation. Although a wide array of devices are
available in the market [7], dose delivery eﬃciencies for dry
powder asthma inhalers range from 3 to 15% for children
and 10 to 30% for adults, indicating that less than one third
of the contained drug actually reaches the lungs; the most
advanced pMDIs deliver only 60% of the inhaled material to
central and intermediate bronchial airways [4].
The preparation of respirable particles with reproducible
and tunable aerodynamic properties remains a challenge [4,
5]. Conventional fabrication of these pharmaceutical aero-
sols for DPIs is accomplished by techniques such as micron-
ization (milling) or spray drying [8]. These formulation
techniques result in polydisperse aerosol populations, with2 Journal of Drug Delivery
large particle size distributions and limited control over par-
ticle shape. Additional formulation challenges arise with
forming dry, nonagglomerating powders comprised of pure
active ingredients, especially biologicals like siRNA, proteins,
and monoclonal antibodies (mAbs). Indeed, there are cur-
rently no marketed dry powder inhaled mAbs or siRNA
therapies. The unmet need for improved aerosol drug deliv-
ery technologies is large; respiratory diseases including
asthma, chronic obstructive pulmonary disease (COPD),
cystic ﬁbrosis, and inﬂuenza are a signiﬁcant cause of mor-
bidityandmortalityworldwide,withanestimated10million
lung-disease-related deaths in 2004 globally and with health
care costs in the US alone of a projected $173billion in 2010
[9, 10].
In this work, we demonstrate the use of a top-down, roll-
to-roll particle nanomolding technology, (PRINT, Particle
Replication in Non-wetting Templates) to fabricate mono-
disperse, nonspherical particles with unprecedented control
over size and shape [11–13] and highlight the beneﬁts that
this approach can have for drug delivery and particularly
respiratory drug delivery. In addition to new results pre-
sented in this paper, we highlight other published studies
that demonstrate the breadth and applicability of PRINT
drug delivery technology for applications beyond respiratory
delivery, including systemic delivery.
In previous eﬀorts, PRINT nanoparticles and micropar-
ticles have been used to study the eﬀects of particle size on
cellular internalization and particle biodistribution in vivo.
Gratton et al. studied the eﬀects of particle size and shape
on cellular internalization and intracellular traﬃcking and
demonstrated signiﬁcant dependence on particle size and
shape in both the internalization rate and internalization
pathways of HeLa cells [14]. Interestingly, the authors
demonstrated that rod-like particles show a higher internal-
ization rate than equivalent diameter cylindrical particles.
Merkel et al. have examined the role that particle modulus
playsinparticlecirculationinvivo,ﬁndingthatlow-modulus
hydrogel microparticles have elimination half-lives of greater
than 90hours [15]. Increasing the stiﬀness of these particles
by increasing hydrogel crosslink density can reduce the
elimination half-life 30-fold and change the accumulation of
these particles from the spleen to the lungs and liver. These
two studies highlight the importance that ﬂexible control
of particle size, shape, and chemistry aﬀords drug delivery
vehicles. Additionally, the PRINT manufacturing process has
been demonstrated at scales relevant to support preclinical
and clinical studies. Liquidia Technologies has initiated a
Phase I clinical study of a PRINT vaccine candidate, demon-
strating the production of GMP pharmaceutical materials
using this novel nanofabrication process, at a scale relevant
to clinical development [16].
The outcome of implementing this particle engineering
approach for dry powder fabrication is improved aerosol
performance applicable to respiratory drug delivery, demon-
strated by incorporation of a variety of pharmaceutically rel-
evant compounds. In vitro results demonstrate that PRINT
particle aerosols possess high respirable dose, high ﬁne par-
ticle fraction, and tunable particle aerodynamic diameter.
In vivo canine deposition studies demonstrate the ability to
inﬂuence dry powder delivery as a function of particle geom-
etry. These results suggest that this tunable particle engi-
neering approach is a versatile platform for enabling next-
generation respiratory drug delivery. We also highlight some
of the utility of PRINT for the production of particles for
small molecule, protein, and oligonucleotide drug delivery,
which demonstrates that PRINT is a versatile formulation
approach and should ﬁnd applicability in oral, parenteral,
and topical dosage forms for multiple disease indications.
2. Methods
2.1. Fabrication of Particles for Drug Delivery Using PRINT
Technology. PRINT is an adaptation of micro- and nano-
molding technologies, rooted in the microelectronics indus-
try, that is used to fabricate monodisperse particles of con-
trolledsizesandshapesusingroll-to-rollmanufacturingpro-
cesses. It allows for the fabrication of monodisperse particles
with precise control over size, shape, composition, and
surface functionalization. Unlike many other particle fabri-
cation techniques, the PRINT method is versatile and gentle
enough to be compatible with the multitude of next-gen-
eration therapeutic and diagnostic agents, including small
molecules, protein biologics, siRNA, and bioabsorbable and
hydrophilic polymer matrix materials with embedded phar-
maceutical cargo.
AnoverviewofthePRINTprocessisoutlinedinFigure 1.
As mentioned previously, the particles produced using the
PRINT process are templated using polymeric micromolds.
The molds themselves arise from replication of a silicon
master template (Figure 1(a)), which is fabricated using ad-
vancedlithographictechniques.Thereplicationofthemaster
templateresultsinaprecisemoldhavingmicro-ornanoscale
cavities. Molding of pharmaceutical materials and/or excip-
ients occurs through spontaneous ﬁlling of the cavities
through capillary forces, with no formation of an intercon-
necting “ﬂash” layer of material between the cavities (Figures
1(b) and 1(c)). The particles are solidiﬁed (Figure 1(d)) and
removed from the mold by bringing the mold in contact
with an adhesive layer that enables the particles to be easily
removed from the mold cavities (Figure 1(e)). At this point
freeﬂowingpowdersorstabledispersionscanbeobtainedby
dissolvingawaytheadhesivelayerfromtheparticles,withthe
option to then be further puriﬁed, chemically modiﬁed, or
analyzed (Figure 1(f)). Particles can be used as suspensions
or dried using evaporation or lyophilization to produce dry
powders.
2.2. Fabrication of Particles for Respiratory Drug Delivery.
PRINT particles were fabricated and isolated as dry powders
as described in previous reports [12, 13, 15, 17, 18]. To
highlight the chemical versatility of PRINT particle technol-
ogy for aerosol delivery of both small molecule and biologic
drugs, particles comprised of proteins such as bovine serum
albumin (BSA, Sigma-Aldrich) and immunoglobulin G
(IgG, Calbiochem), polymers such as poly-lactic-co-glycolic
acid (PLGA, Mw 30K, Polysciences), and pharmaceuti-
cally relevant compounds such as itraconazole (Spectrum
Chemical), zanamivir (Haorui USA), DNase (WorthingtonJournal of Drug Delivery 3
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Figure 1: Schematic illustration of the PRINT process. (a) Features on a hard silicon master template are replicated with high ﬁdelity (b) to
obtain a soft, polymeric mold with micro- and nanocavities that can then be (c) ﬁlled with relevant particle matrix and (d) extracted out of
the mold and onto a harvest array for (e) particle collection and puriﬁcation.
Biochemical),andsiRNA(Dharmacon)werefabricated.Mo-
nodisperse particles from these molds were collected in
various aqueous and organic suspensions: for particles con-
sisting of non-water-soluble matrices, such as polymeric and
the small molecule itraconazole, distilled water was used
to collect the particles from the array; for particles con-
sisting of water-soluble matrices such as zanamivir, DNase,
and siRNA, isopropyl alcohol was used to collect the
particles from the array. To make porous particles, sacriﬁcial
poly(vinylpyrrolidone) porogen are comolded with the drug
or drug/excipient blend and selectively removed during the
harvesting step. Finally, particles were lyophilized from water
or tert-butanol in order to obtain dry powder PRINT parti-
cles. Itraconazole powder (Spectrum Chemical) was micron-
ized for aerodynamic particle size comparison testing with
PRINT particles. Micronization was performed using one
pass through the Glen Mills Laboratory Jet Mill.
2.3. Chemical and Bioactivity Analyses of Pharmaceutical
Compounds in PRINT Particles. PRINT particles composed
of small molecules and biologic materials were analyzed
to conﬁrm retention of chemical structure and biological
activityduringthePRINTprocess.Allchromatographicana-
lyses were performed using the Agilent 1100 liquid chro-
matography system and analyzed in Empower. A gradi-
ent reverse-phase high-performance liquid chromatography
(RP-HPLC)methodforitraconazoleanalysiswasbasedoﬀof
the European Pharmacopoeia (EP) 5.0 method for the com-
pound [19]. Brieﬂy, the chromatographic procedure is a
stability-indicating EP method for itraconazole in which the
detection has been modiﬁed for use with a diode array. This
gradient elution method used a Phenomenex Prodigy ODS
(3)100angstrom,4.0×100mm,3μmanalyticalcolumnwith
mobile phase A containing 27.2g/L tetrabutylammonium
hydrogen sulphate in HPLC grade water and mobile phase
B containing acetonitrile and used a ﬂow rate of 1.5mL/min
with the following gradient conditions: 0 to 20min, 20 to
50%mobilephaseB;20to25min,50%mobilephaseB;25to
30min, 20% mobile phase B. Itraconazole was detected with
adiodearrayultraviolet(UV)measurementat257+/−5nm
with reference background correction at 375 +/− 25nm and
at a retention time of 14.42minutes.
A gradient hydrophilic interaction (HILIC)-HPLC
method was used for analysis of zanamivir. Brieﬂy, a Waters
Atlantic HILIC Silica 5μm, 4.6 × 100mm analytical column
was used with mobile phase A containing 10mM ammo-
nium acetate in 1% methanol and 0.05% phosphoric acid
in order to maintain a pH of 3 to 4 and mobile phase B
containing 0.1% phosphoric acid in acetonitrile. The meth-
od used a ﬂow rate of 1.0mL/min with the following gradi-
ent conditions: 0 to 2min, 80% mobile phase B; 2 to 7min,
80 to 60% mobile phase B; 7 to 12min, 60% mobile phase B;
12 to 17min, 80% mobile phase B. Zanamivir was detected
by UV measurement at 230nm and at a retention time of
5.52minutes.
A gradient super-anionic-exchange-(SAX-) HPLC meth-
od was used for analysis of siRNA. Brieﬂy, a Dionex BioLC
DNAPac PA 200 4 × 250mm analytical column was used
with mobile phase A containing 25mM NaClO4 and 10mM
Tris, 20% ethanol and mobile phase B containing 250mM
NaClO4 and 10mM Tris, 20% ethanol, but at a pH of ap-
proximately 7.0. The method used a ﬂow rate of 1.0mL/min
withacolumntemperatureof40degreesCandthefollowing
gradient conditions: 0 to 8min, 0–100% mobile phase B; 8
to 10min, 0% mobile phase B. siRNA was detected by UV
measurement at 260nm and had a retention time of 6.37
minutes.
An isocratic size exclusion chromatography (SEC) meth-
od was used for analysis of DNase. Brieﬂy, GE Superdex 75
5/150 GL column was used with PBS. The method used a
ﬂow rate of 0.3mL/min, and the protein was detected by UV
measurement at 280nm and at a retention time of 5.14 mi-
nutes. In addition to SEC analysis, a DNA-Methyl Green as-
say was also used to characterize the bioactivity of DNase,
as previously performed by others [20]. Brieﬂy, DNA-Methyl
Green (Sigma-Aldrich) was solubilized in 0.05M Tris buﬀer
to a concentration of 0.2mg/mL. DNase activity, both un-
processed standards (Sigma Aldrich and Worthington) and4 Journal of Drug Delivery
DNase from PRINT particles, was obtained by adding DNase
samples individually to DNA-Methyl Green and measuring
the Methyl Green light absorbance at 640nm at 2minute
intervals. These measurements were used to obtain an ini-
tiallinearrateofDNA-MethylGreendegradation,whichcor-
relates directly to DNase activity.
2.4. In Vitro Characterization of Particle Size. Aerodynamic
particle sizing of all PRINT aerosols was performed using the
aerodynamic particle sizer (APS) spectrometer (Model no.
3321, TSI Inc. Shoreview, MN, USA). Dry powder aerosols
were dispensed into an aerosol generator using an insuﬄator
device and a volume-calibrated hand pump (Penn Century
Inc., PA, USA).
Next-generation impactor (NGI) experiments were used
to compare the aerodynamic size distribution of PRINT
zanamivir formulations to Relenza. Before testing, NGI
stages were coated with silicone oil. To test PRINT formula-
tions, 5mg of PRINT-zanamivir particles were loaded into
a size 3 HPMC capsule, which was loaded into a Monodose
device (Plastiape SpA). The loaded Monodose device was at-
tached to an NGI (MSP Model 170) and tested using a
60L/min ﬂow rate for 4seconds. Deposited drug was rinsed
from the capsule, the device, device adapter, induction
port, ﬁlter, and each stage of the NGI using 5 to 25mL
HPLC grade water, and the zanamivir content in each rins-
ate was measured using HPLC and compared to standard
curves to determine the absolute weight of zanamivir in
the capsule, device, and impactor. Similar methodology was
used to measure the aerodynamic particle size distribution
of Relenza, with the exception that preseparator stages were
usedtodeterminethedepositeddoseoflarge(>10μm)zana-
mivir/lactose agglomerates.
Laser diﬀraction was used to determine the geometric
size of micronized itraconazole crystals. Speciﬁcally, meas-
urements were performed using a Sympatec HELOS instru-
ment, operated at 5 bar primary pressure and 105mbar sec-
ondary pressure.
2.5. Gamma Scintigraphy In Vivo Canine Lung Deposition
Imaging. Torusaerosols(1.5μmand6μm)fortheinvivoca-
nine deposition study were fabricated out of a lactose-albu-
min-leucine blend (64/32/4 mass ratio) and were fur-
ther labeled with technitium-99 (Tc99m) by isopropyl
alcohol coevaporation. Na¨ ıve (unlabeled) PRINT particles
were mixed with Tc99m in isopropyl alcohol. Ratios of
Tc99m:PRINT particle:IPA were held at 50mCi:50mg:
0.75mL. The mixture was the gently shaken to mix without
coating the material on sides of the vials. The mixture was
then evaporated under a gentle stream of N2. The labeled
particles were then immediately loaded into insuﬄators and
used for either validation studies or canine exposures.
In order to conﬁrm the radiolabeling process, the mass
median aerodynamic diameter (MMAD) of the materials
before and after labeling and the activity median aerody-
namic diameter (AMAD) were determined with a next-gen-
eration impactor (NGI). The NGI was operated at 30L/min
for all testing. The MMADs of both labeled and na¨ ıve aer-
osols were determined via diﬀerential weight analysis of the
NGI cups. Following diﬀerential weight analysis, the cups
were rinsed with 3mL of water and the water was transferr-
ed into a 20mL scintillation vial. The activity in each cup
was quantiﬁed with a radio isotope counter. All data were
processed to determine the MMAD/AMAD and the geo-
metric standard deviation (GSD) for each aerosol. Based
on initial results, it was decided to place a cyclone (URG
Corp, model URG-2000-30EC) inline with the aerosol deliv-
ery system to remove large agglomerates and achieve an ac-
ceptable correlation between the na¨ ıve aerosols and Tc99m
activity.
In order to estimate the amount of material dosed using
thecanineendotracheal exposure system,thedeliverysystem
eﬃciency was ﬁrst determined for each particle group. This
was performed by loading the dry powder reservoir with
known amounts of each material (1.5 and/or 6.0μmt o r u s
particles)andcollectingaerosolizedpowderonaﬁlterplaced
at the exit of the endotracheal tube. The amount of material
on the ﬁlter and the amount of material delivered from
the devices were determined via diﬀerential weight analysis.
The delivery eﬃciency was calculated as the percentage of
material delivered from the dry powder reservoir device that
exits the endotracheal tube and is ultimately available to the
lower respiratory tract.
At the time of exposure, multiple dry powder reservoirs
were loaded to target an aerosol delivery of 10mCi and en-
sure suﬃcient Tc99m deposition in the canine lungs for
image analysis. Prior to being exposed, animals were placed
on isoﬂuorane anesthesia and apnea was induced by hyper-
ventilation.Immediatelyfollowingtheaerosolexposures,the
endotracheal tube was removed and the dogs were trans-
ferred to the Siemens E.Cam clinical SPECT gamma camera
anda10minuteplanargammaimagewascollected.Thetime
lapsed from the start of aerosol exposures until the start of
imaging was ∼1.5 to 2minutes, and the time from the start
of aerosol exposures until the completion of the imaging
was typically ∼12minutes. During image acquisition, the
dry powder reservoirs were quantiﬁed for radioactivity to
determine the amount of activity aerosolized. This value was
then multiplied by the predetermined delivery eﬃciency in
order to estimate the lower respiratory tract dose, or dose
presented at the exit of the endotracheal tube, for each ex-
periment.
2.6. Canine Lung Deposition Image Analysis. Image analysis
was performed with the Siemens ICON software to deter-
mine the activity in two canine regions of interest (ROI) for
each animal: the lungs and the trachea. In order to correlate
the counts in each ROI to activity, a standard curve was
prepared for the gamma camera to deﬁne the relationship
betweenactivity(measuredwitharadioisotope counter)and
counts (from the image analysis). After converting measured
counts to radioactivity, the quantiﬁed amount of activity in
the lung ROI was then divided by the quantiﬁed amount
of activity in the lung ROI in order to determine whole
lung deposition counts normalized to trachea counts for
each animal. Statistical diﬀerences in this measurement were
evaluated by paired, two-tailed t-test across the four animals
used for lung deposition imaging.Journal of Drug Delivery 5
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Figure 2: SEM micrographs of diverse PRINT aerosols. (a) BSA/Lactose 200 × 200nm cylinders; (b) IgG/Lactose10μm pollen; (c) 30K
PLGA 3μm cylinders; (d) itraconazole 1.5μm torus; (e) itraconazole 3μm torus; (f) itraconazole 6μm torus; (g) zanamivir 1.5μm torus; (h)
DNAse 1.5μm torus; (i) siRNA 1.5μm torus.
3. Results
3.1. Precisely Engineered Particles Containing Pharmaceuti-
cally Relevant Components. To illustrate the delivery of rele-
vant therapeutic compounds to the respiratory tract, we fab-
ricated particles with independent control of particle size,
shape, and composition. An array of SEM micrographs is
shown in Figure 2 highlighting PRINT’s versatility: BSA/lac-
tose blend 200 × 200nm cylinders (Figure 2(a)); IgG/lactose
blend 10μm“ p o l l e n ”( Figure 2(b)); poly-lactic-co-glycolic
acid (PLGA, Mw 30K) 3μm cylinders (Figure 2(c)); itra-
conazole (marketed as Sporanox for treatment of fungal
infection) molded into 1.5μm, 3μm, and 6μm torus parti-
cles (Figures 2(d)–2(f)); 1.5μm torus particles comprised
of pharmaceutically relevant compounds including zana-
mivir (marketed as Relenza for treatment of inﬂuenza)
(Figure 2(g)); bovine DNase (recombinant human DNase
is marketed as Pulmozyme for treatment of cystic ﬁbro-
sis) (Figure 2(h)); siRNA (Dharmacon) (Figure 2(i)). The
“pollen” shape in Figure 2(b) is a biomimetic design, based
on the shape of the pollen Eperua schomburgkiana.
In order to conﬁrm that the PRINT particle fabrication
process used to generate engineered aerosols did not alter the
chemical structure of pharmaceutical compounds, analytical
tests were performed to determine the compound integrity
following fabrication as compared to the unprocessed or
reference compound. Purity of compounds in PRINT par-
ticles relative to unprocessed or reference compound was
measured to be 99.6% for itraconazole (RP-HPLC), 100%
for zanamivir (HILIC-HPLC), 99.2% for siRNA (SAX-
HPLC), and 99.0% for DNase (SEC). Additionally, IC50
in DNA-Methyl Green assay yielded DNase IC50 values
for reference DNase (Worthington) and PRINT-DNase of
26.5 and 18.8Kunitz units/mL, respectively, indicating that
PRINT particle fabrication does not alter DNase bioactivity.
3.2. Aerodynamic Characteristics of PRINT Aerosols. Physical
characterization of PRINT aerosols conﬁrmed the ability to
produce highly dispersible aerosols with controllable and
narrow aerodynamic size distributions. Figure 3(a) demon-
strates the capability to tune particle aerodynamic size on
the basis of particle design. We fabricated torus particles6 Journal of Drug Delivery
with geometric sizes 1.5μm, 3μm, and 6μmt o r u sa n d
measured their aerodynamic characteristics using a time-of-
ﬂight aerodynamic particle sizer (APS). For these particles,
porogen was added to the formulation, then subsequently
removed to produce porous particles. The mass median
average aerodynamic diameters (MMAD) of these particles
were measured to be of 0.83μm, 1.27μm, and 2.57μmw i t h
geometric standard deviations (GSD) of 1.68μm, 1.47μm,
and 1.91, respectively.
To compare the size distributions of PRINT aerosols
to conventional fabrication techniques (Figure 3(b)), we
compared the mass-weighted aerodynamic particle size dis-
tribution (mass median aerodynamic diameter, MMAD) of
1.5μmPRINTcylinderscomposedofitraconazoletothepar-
ticle size distribution of jet-milled itraconazole (geometric
size ×10 = 0.77μm; ×50 = 2.79μm; ×90 = 7.42μm). Jet
milling is the most commonly utilized technique for pre-
paration of respirable aerosol particles. The PRINT aerosol
had a narrower distribution and a higher fraction of drug
in the respirable range (less than 5μm), indicating that the
aerodynamicpropertiesoftheseparticlesarebettersuitedfor
inhalation therapies. Moreover, according to well-accepted
correlations of aerodynamic particle size and lung deposi-
tion, it can be expected that the 1μm cylinder particles will
have enhanced deposition in peripheral airways (alveoli and
respiratory bronchioles) compared to the larger particles.
The precise control over aerodynamic size of PRINT aerosols
may be clinically useful for local drug delivery to the lungs
by enhancing deposition eﬃciency at the site of disease and
limiting unintended oﬀ-target eﬀects [21].
3.3. Engineered PRINT Aerosols Exhibit Increased Aerosol
Delivery In Vitro. We compared the in vitro performance
of pharmaceutically relevant PRINT particle aerosols to a
dry powder marketed product. This was carried out using
Relenza (GlaxoSmithKline), a small molecule DPI indicat-
ed for treatment of inﬂuenza, which contains the active
pharmaceutical ingredient, zanamivir (5mg), blended with
micronized lactose (20mg). 1.5μm torus PRINT-zanamivir
formulations were prepared, directly packaged into capsules,
and aerosolized from a low-resistance DPI device (Mono-
dose, Plastiape SpA). Both PRINT-zanamivir and Relenza
formulations were characterized with a next-generation im-
pactor(NGI).AsshowninFigures4(a)and4(b),thePRINT-
zanamivir formulation resulted in signiﬁcantly improved
delivery compared to Relenza. For the same ﬁll weight
(5mg), the PRINT zanamivir dosage form showed a smaller
MMAD, a similar GSD, 3 to 4 times higher ﬁne particle frac-
tion (FPF) and respirable dose, and 4 to 5 times more dep-
osition of material in the size range of less than 1.6μm. It is
expected that the device retention of the PRINT-zanamivir
formulation could be signiﬁcantly decreased with tuning of
the ﬁll weight or device characteristics, which is beyond the
scope of the work presented here. These results indicate that
ﬁner engineered PRINT particles should correlate to super-
ior drug delivery to the lower respiratory tract (Figure 4(b)).
Based on literature studies of the deposition patterns of
Relenza in healthy human volunteers, it is known that
77% of the emitted drug from the commercial product
is deposited in the oropharynx rather than the lung [22].
Thus, the in vitro results presented here suggest that the
PRINT-zanamivir aerosol would translate to signiﬁcantly
more eﬃcient lung delivery compared to Relenza.
3.4. PRINT Aerosols with Narrow Size Distributions Exhibit
Distinct In Vivo Lung Deposition Patterns. Finally, we
demonstrated the ability of PRINT particle aerosols to
control in vivo pulmonary delivery using a canine deposition
model. PRINT aerosols composed of lactose, albumin, and
leucine (64/32/4 mass ratio) were prepared, radiolabeled
with technetium-99, and aerosolized into the respiratory
tract of beagle dogs using an endotracheal dosing apparatus.
As shown in the gamma scintigraphic images (Figure 4(c)),
signiﬁcantly more whole-lung deposition was achieved with
1.5μmv e r s u s6 μm torus particles (1.3μma n d4 . 6 μm
MMAD, resp.), as would be expected from the relative aero-
dynamic sizes of these particles. Image analysis and quantiﬁ-
cationoftheradioactivitycountsconﬁrmedthisobservation.
In addition, the torus 1.5μm particles showed a greater
than twofold enhancement of whole-lung deposition counts
normalized to trachea deposition. This ability to tailor par-
ticle lung deposition could have broad applicability for res-
piratory drug delivery, particularly in scenarios where peri-
pheral lung deposition should be enhanced or avoided de-
pending on clinical application.
4. Discussion
The PRINT fabrication approach predictably controls par-
ticle geometric and aerodynamic features, a diﬀerentiating
attribute as compared to traditional particle generation ap-
proaches. In particular, micromolding strategies such as
PRINT represent one of the only methods to precisely con-
trolparticleshapeandsize.ForPRINT,theparticlegeometry
is directly derived from the semiconductor wafer, bringing
inherentnanoscaleprecisiontotheparticlegeometryandof-
feringthecapabilitytogenerateunique,nonsphericalshapes.
It is possible to control geometric features such as length,
aspectratio,andedgecurvature,aswellasaddinguniquefea-
tures such as fenestrations and biomimetic designs, as shown
in Figure 2. The capability of PRINT to prepare micro- and
nanoparticles of a diverse set of materials is due to the
ability to mold materials in a variety of physical forms. In
addition to the detailed studies presented here, particles have
beenpreparedbypolymerization[11]orsolventevaporation
[23]. This ﬂexibility lends itself to the preparation of
pharmaceutically relevant particles such as hydrogels [15],
PLGA controlled-release systems [13], stimuli-responsive
particles [17], suspension formulations [14], or dry powder
aerosols as presented here (Figures 2 and 3). This ability
to control particle size, shape, and uniformity should also
ﬁnd advantageous use in many dosage forms, including oral,
topical, and parenteral products.
Microfabrication techniques such as PRINT oﬀer the ad-
vantage of deterministic control of particle geometry that is
inherentfromtheuseofsemiconductormanufacturingtech-
niques. In the case of PRINT technology, the same master
template can be used to create each batch of micromolds andJournal of Drug Delivery 7
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Figure 3: Aerodynamic characterization of PRINT aerosols. (a) SEM micrographs and aerodynamic performance of 1.5μm, 3μm, and 6μm
particles by APS. PRINT aﬀords precise control over particle geometric size and aerodynamic size. (b) SEMs and aerodynamic distributions
of jet-milled itraconazole aerosols compared to 1μm PRINT cylinder particles made out of itraconazole. PRINT-itraconazole particles result
in a narrower size distribution and higher available respirable fraction.
particles for a particular size and shape. Thus, each batch
of particles possesses high uniformity and batch-to-batch
consistency, regardless of the batch size. In addition, the
uniform particle populations that are produced lend them-
selves to straightforward in-process characterization using a
number of standard particle sizing methods, such as micro-
scopy and light scattering. These features make the PRINT
technology attractive from the perspective of compliance
with Quality-by-Design directives from the FDA.
From a formulation perspective, PRINT technology has
been shown to be a versatile approach to deliver many classes
of therapeutic compounds and excipients. Particle size can
be controlled over several orders of magnitude, from the
sub-100nm scale to hundreds of microns. In traditional
fabrication methods, particle chemical composition and
physical characteristics such as geometric or aerodynamic
size are inherently coupled, for example, the molecular
properties of a small molecule pharmaceutical ingredient are
known to impact the particle size distribution of micronized
particles, whereas the solubility and drying kinetics of
precursor solutions can impact the particle size distribution
of spray-dried particles [8]. In contrast, micromolded
particle engineering has the ability to deﬁne the particle size
and shape independent of the input material properties,
which was demonstrated by fabricating particles of identical
geometry yet comprising hydrophilic and hydrophobic small
molecules, proteins, or nucleic acids (Figures 2(d)–2(i)).
While particularly relevant for aerosol lung delivery, this
ability to independently control particle composition and
physical size should ﬁnd utility in multiple dosage forms and
routes of administration.
S m a l lm o l e c u l ed r u gc o m p o u n d sc a nb ef o r m u l a t e da s
drug alone or drug/excipient mixtures with tunable loading.
Enlowetal.demonstratedtheproductionofPLGA/docetaxel
PRINT nanoparticles with up to 40% chemotherapeutic
loading [13]. This ﬁnding is in contrast to typical polymer
nanoparticle drug delivery systems produced by emulsion
[24], nanoprecipitation [25], and ultrasonication [26] that
have theoretical drug loading of less than 15% and variable
encapsulation eﬃciency. Furthermore, the authors demon-
strated the ability to independently tune particle size, shape,
and drug loading. In vitro results indicated that potency of
these PLGA-docetaxel nanoparticles was up to 10x greater
than Taxotere, a commercially marketed micellar formula-
tion of docetaxel. In this work, we highlight the ability of
PRINT to fabricate particles of neat small molecule drugs.
Figures 2(d)–2(f) show particles composed of 100% itra-
conazole, prepared by molding an amorphous itraconazole
glass. Particles composed of zanamivir were also fabricated
(Figure 2(g)), and both itraconazole and zanamivir particles
showedgoodaerosoldeliveryperformanceinvitro(Figures 3
and 4).
PRINT particles can be prepared from protein and
oligonucleotide therapeutic agents as well. Kelly and DeSi-
mone demonstrated the capability to use PRINT technology
to fabricate monodisperse particles of albumin and insulin
without causing agglomeration of the protein [12]. In this
work, we demonstrate molding of DNase, a therapeutic8 Journal of Drug Delivery
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Figure 4: Favorable properties of PRINT aerosols for dry powder pharmaceutical use. (a, b) Comparison of 1.5μm torus PRINT-zanamivir
particles against the marketed product Relenza (active pharmaceutical ingredient zanamivir) using an NGI. (b) PS: preseparator; RSD:
relative standard deviation. (c) Whole lung deposition by gamma scintigraphy in canine shows increased whole-lung deposition of 1.5μm
(right, 1.3μm MMAD) torus aerosols versus 6.0μm (left, 4.6μm MMAD) torus aerosols.
protein for cystic ﬁbrosis (marketed as Pulmozyme).
Figure 2(h) shows 1.5μm torus particles composed of
DNase. Size exclusion chromatography of PRINT-DNase
microparticles shows minimal agglomeration of the protein,
and in vitro bioassay measurements demonstrate equivalent
enzyme activity to na¨ ıve DNase. Oligonucleotide molecules
such as siRNA therapeutics were also successfully molded as
particles (Figure 2(i)) with retention of chemical structure.
Taken together, these data demonstrate that PRINT particles
can be formed of biological materials without aggregat-
ing/denaturing the molecule or changing its functionality.
Micromolded particles produce high-performance aero-
sols that possess tunable aerodynamic diameters and narrow
aerodynamic size distributions. This control over aerosol
characteristicswasdemonstratedacrossawiderangeofaero-
dynamic diameters within the respirable range (Figure 3(a))
and through diﬀerential in vivo lung deposition based
on particle size (Figure 4(c)). In addition, PRINT aerosolsJournal of Drug Delivery 9
achieve an increased respirable dose and decreased MMAD,
including the dose fraction below 1.6μm, compared to
aerosols generated by traditional micronization processes
(Figures 3(b) and 4(a)). These attributes are expected to
translate into more eﬃcient respiratory drug delivery for a
wide range of therapeutics that are intended to deposit in
thelungperiphery.Importantly,theaerosolizationofPRINT
particle dry powders does not require the use of bulking
excipients, such as lactose, for particle dispersion, as is often
the case for dry powder products. Elimination of bulking
agents potentially simpliﬁes the chemistry, manufacturing,
a n dc o n t r o lp r o c e s s e sr e q u i r e dt od e v e l o pd r yp o w d e r
products, as well as mitigating the potential for excipient-
induced user side eﬀects.
The micromolding particle fabrication approach pre-
sented here also holds the potential to engineer dry powder
aerosols optimized for speciﬁc disease targets. There are a
number of instances where more precise respiratory drug
delivery could be useful, as has been demonstrated by others.
Particle aerodynamic size and regional drug deposition has
beenshowntoinﬂuencepharmacodynamicresponsesindis-
easessuchasasthmaandcysticﬁbrosis.Usmanietal.demon-
stratedthat6.0μmMMADalbuterolaerosolsimproveforced
expiratory volume (FEV1) in asthmatic subjects to a greater
degree than 3μmo r1 . 5μm aerosols. The authors correlat-
ed the enhancements FEV1 to higher central lung deposi-
tion (conﬁrmed by scintigraphy) and postulated that the
pharmacodynamic advantage of these 6.0μm aerosols was
related to greater deposition in proximity to conducting air-
way smooth muscle tissue [27]. In another study in cystic
ﬁbrosispatients,improvedforcedexpiratoryfraction(FEF75)
was observed for DNase aerosols delivered preferentially to
the small airways compared to the large airways. This data
suggests that enhanced deposition of DNase at the site(s) of
diseasepathologycouldbeneﬁtpatientlungfunction[28].In
addition, it is reasonable to expect that enhanced deposition
in the alveolar region may be favorable for applications
such as systemic delivery of therapeutics via the lung [21].
ThesestudiessuggestthattechnologiessuchasPRINT,which
possess the ability to engineer particles with desirable aerosol
and deposition characteristics, could ultimately result in
inhaled products with enhanced eﬃcacy when applied to
the appropriate disease and therapeutic compound. In par-
ticular, the beneﬁts of diﬀerential lung deposition and
eﬃcientlungdeliv erywillbeparticularlyusefulforexpensiv e
therapeutic agents such as biologics or highly potent, narrow
therapeutic index compounds.
Lastly, particle shape is known to inﬂuence all stages of
pulmonary drug delivery: from entrainment and deagglom-
eration into a disperse aerosol [21, 29, 30], to aerodynamic
characteristics and deposition [8, 30–34], to mucociliary
clearance and macrophage uptake [14, 35, 36]. Others have
demonstrated that shape has an impact on particle aero-
dynamic characteristics through studies on simple shapes,
such as rods, plates, ﬁbers, and spheres [30, 31]. Though
particle shape is known to be a critical factor of aerosol
properties,thoroughexplorationofitseﬀecthasbeenlimited
by current fabrication methods of aerosol particles [31].
Controlling particle shape thus provides an opportunity to
systematically optimize the eﬀect of shape on these stages of
drug delivery. Microfabrication techniques such as PRINT
oﬀer a promising strategy to control particle shape, and
morethoroughinvestigationsontheimpactofparticleshape
on lung deposition, clearance, and cellular internalization
are currently underway in order to better characterize the
speciﬁc beneﬁts particle shape may hold for respiratory drug
delivery.
5. Conclusion
In summary, coopting the top-down manufacturing capabil-
ities of the microelectronics industry enables the generation
of high-precision particle-based drug delivery systems that
arecompatiblewithnovelandexistingformulationstrategies
and dosage forms. In particular, the PRINT process is
well suited for the production of high-performance aerosol
particles for respiratory drug delivery. Precise control over
size and shape allows for deﬁned aerodynamic properties,
which, in turn, leads to enhanced aerosol performance and
diﬀerentiallungdepositioninvivo.Inadditiontothebeneﬁts
impartedbycontroloverparticlesizeandshape,micromold-
ingispresentedasaversatilestrategyforformulatingparticle
systems of small molecules, biologics, oligonucleotides, and
drug/excipient mixtures. Overall, micro-molding is a viable
particle design strategy that may address challenges existing
forr espirat orydrugdeli v eryandotherdosageforms,ther eb y
constituting a promising opportunity for the development of
next-generation therapeutics.
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